In case of head and neck squamous cell carcinoma (HNSCC), expression of PD-1 ligands, PD-L1 and PD-L2, within the tumor has been correlated with poor prognosis, suggesting that α-PD-1 therapy is a relevant approach to anti-tumor immunity [7–9]. This evidence concerns the gene PDCD1 and neoplasm.